Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price
Orchard Therapeutics Revenue
Orchard Therapeutics had revenue of $21.84M in the twelve months ending September 30, 2023, with 35.21% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $6.30M with 9.09% year-over-year growth. In the year 2022, Orchard Therapeutics had annual revenue of $22.66M with 1,252.54% growth.
Revenue (ttm)
$21.84M
Revenue Growth
+35.21%
P/S Ratio
34.65
Revenue / Employee
$131,560
Employees
166
Market Cap
756.82M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 22.66M | 20.98M | 1,252.54% |
Dec 31, 2021 | 1.68M | -920.00K | -35.45% |
Dec 31, 2020 | 2.60M | 82.00K | 3.26% |
Dec 31, 2019 | 2.51M | 437.00K | 21.05% |
Dec 31, 2018 | 2.08M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionORTX News
- 24 days ago - Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day - GlobeNewsWire
- 2 months ago - Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 - GlobeNewsWire
- 2 months ago - Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List - GlobeNewsWire
- 4 months ago - Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy - GlobeNewsWire
- 4 months ago - Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. - GlobeNewsWire
- 4 months ago - US approves first gene therapy for rare genetic disease - Reuters
- 6 months ago - Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome - GlobeNewsWire
- 6 months ago - Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium - GlobeNewsWire